BR112015001096A2 - derivados de di e tri-heteroaril como inibidores de agregação de proteína - Google Patents

derivados de di e tri-heteroaril como inibidores de agregação de proteína

Info

Publication number
BR112015001096A2
BR112015001096A2 BR112015001096A BR112015001096A BR112015001096A2 BR 112015001096 A2 BR112015001096 A2 BR 112015001096A2 BR 112015001096 A BR112015001096 A BR 112015001096A BR 112015001096 A BR112015001096 A BR 112015001096A BR 112015001096 A2 BR112015001096 A2 BR 112015001096A2
Authority
BR
Brazil
Prior art keywords
protein aggregation
triheteroaryl
derivatives
aggregation inhibitors
methods
Prior art date
Application number
BR112015001096A
Other languages
English (en)
Inventor
Wrasidlo Wolfgang
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of BR112015001096A2 publication Critical patent/BR112015001096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

resumo “derivados de di e tri-heteroaril como inibidores de agregação de proteína” a presente invenção está relacionada a certos derivados de di e tri-heteroaril, composições farmacêuticas que os contêm e métodos de uso deles, incluindo métodos para a prevenção, reversão, retardo, ou inibição de agregação de proteína, e métodos de tratamento de doenças que são associadas com agregação de proteína, incluindo doenças neurodegenerativas como doença de parkinson, doença de alzheimer, doença de corpo de lewy, e atrofia de múltiplos sistemas.
BR112015001096A 2012-07-16 2013-07-16 derivados de di e tri-heteroaril como inibidores de agregação de proteína BR112015001096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
BR112015001096A2 true BR112015001096A2 (pt) 2017-06-27

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001096A BR112015001096A2 (pt) 2012-07-16 2013-07-16 derivados de di e tri-heteroaril como inibidores de agregação de proteína

Country Status (15)

Country Link
US (1) US9284309B2 (pt)
EP (1) EP2872143B1 (pt)
JP (1) JP2015522617A (pt)
KR (1) KR20150031481A (pt)
CN (1) CN104703604A (pt)
AU (1) AU2013290361A1 (pt)
BR (1) BR112015001096A2 (pt)
CA (1) CA2877983A1 (pt)
ES (1) ES2661394T3 (pt)
HK (1) HK1210598A1 (pt)
IL (1) IL236712A0 (pt)
IN (1) IN2015DN01171A (pt)
MX (1) MX2015000618A (pt)
RU (1) RU2015104962A (pt)
WO (1) WO2014014937A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040274T2 (hu) * 2014-01-29 2019-03-28 Ucb Biopharma Sprl Heteroarilamidok a proteinaggregáció inhibitoraiként
US10975066B2 (en) * 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CA3048946A1 (en) * 2017-01-26 2018-08-02 Ucb Biopharma Sprl Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
KR20190112022A (ko) 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 바이사이클릭 비스-헤테로아릴 유도체
WO2018158160A1 (en) 2017-02-28 2018-09-07 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782878B2 (en) * 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU2001290940A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
JP2005536533A (ja) * 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
ME02053B (me) 2009-04-30 2015-05-20 Glaxo Group Ltd Oksazol supstituisani indazoli kao inhibitori pi3-kinaze
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CN102725284A (zh) 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物
WO2011146748A1 (en) 2010-05-21 2011-11-24 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Also Published As

Publication number Publication date
EP2872143B1 (en) 2017-12-13
CN104703604A (zh) 2015-06-10
WO2014014937A1 (en) 2014-01-23
AU2013290361A1 (en) 2015-02-05
RU2015104962A (ru) 2016-09-10
US20150183776A1 (en) 2015-07-02
IN2015DN01171A (pt) 2015-06-26
US9284309B2 (en) 2016-03-15
MX2015000618A (es) 2015-04-10
JP2015522617A (ja) 2015-08-06
EP2872143A4 (en) 2015-12-02
HK1210598A1 (en) 2016-04-29
ES2661394T3 (es) 2018-03-28
IL236712A0 (en) 2015-02-26
EP2872143A1 (en) 2015-05-20
CA2877983A1 (en) 2014-01-23
KR20150031481A (ko) 2015-03-24

Similar Documents

Publication Publication Date Title
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
CO2017011851A2 (es) Compuestos novedosos
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
DOP2016000195A (es) Compuestos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
CY1120348T1 (el) Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
BR112016024571A2 (pt) composto de 1,2,4-triazina dissubstituído
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112015019412A2 (pt) inibidores de bace1
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements